TESTBANK
Pharmacotherapeutics For Advanced Practice APractical Ap mo mo mo mo mo mo
proach 5th Edition By Arcangelo; Wilbur; Ch 1 to 56 mo mo mo mo mo mo mo mo mo
Tableofcontent m
o m
o
Chapter I Issues for the Practitioner in Drug Therapy
m o m o mo mo mo mo mo mo
Chapter 2 Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
mo mo mo mo mo mo mo mo
mo
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics
mo m o mo mo mo m o mo mo m o mo mo
Chapter 4 Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
mo mo mo mo mo mo mo mo mo mo
Chapter 5 Pharmacotherapy Principles in Older Adults
mo mo mo mo mo mo
Chapter 6 Principles of Antimicrobial Therapy
mo mo mo mo mo mo
Chapter 7 Pharmacogenomies
mo mo
Chapter 8 The Economics of Pharmacotherapeutics
mo mo mo mo mo mo
Chapter 9 Pharmacotherapy of Pain Management
mo mo mo mo mo
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
mo mo mo mo mo mo mo mo mo mo
Chapter 11 Cannabis and Pain Management
mo mo mo mo mo
Chapter 12 Contact Dermatitis
m o mo mo
Chapter 13 Fungal, Viral, and Bacterial Infections of the Skin C
mo mo mo mo mo mo mo mo mo mo
hapter 14 Psoriasis
mo mo
Chapter I5 Acne Vulgaris and Rosacea
mo mo mo mo mo mo
Chapter 16 Ophthalmic Disorders
mo mo mo
Chapter I7 Otitis Media and Otitis Externa C
mo mo mo mo mo mo mo
hapter I8 Hypertension
mo mo
Chapter I9 Hyperlipidemia
m o mo
Chapter 20 Chronic Stable Angina and Myocardial Infarction
mo mo mo mo mo mo mo
mo Chapter 2I Heart Failure
mo mo mo
Chapter 22 Arrhythmias
mo mo
Chapter 23 Respiratory Infections
mo mo mo
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease
mo mo mo mo mo mo mo mo
Chapter 25 Gastric, Functional, and Inflammatory Boẉel Disorders
mo mo mo mo mo mo mo mo
Chapter 26 Gastroesophageal Reflux Disease and Peptic Ulcer Disease
mo mo mo mo mo mo mo mo
mo Chapter 27 Liver Diseases
mo mo mo
,Chapter 28 Urinary Tract Infection
mo m o mo mo
Chapter 29 Prostatic Disorders and Erectile Dysfunction
mo mo mo mo mo mo mo
Chapter 30 Overactive Bladder
mo mo mo
Chapter 3I Sexually Transmitted Infection
mo mo mo mo
s mo
Chapter 32 Osteoarthritis and Gout
mo mo mo mo mo
Chapter 33 Osteoporosis mo mo
Chapter 34 Rheumatoid Arthritis
mo mo mo mo
Chapter 35 Headaches mo mo
Chapter 36 Seizure Disorders
mo mo mo mo
Chapter 37 Alzheimer's Disease
mo mo mo m o
Chapter 38 Parkinson's diseas
mo mo mo
e
Chapter 39 Major Depressive Disorder and Bipolar Disorders
mo mo mo mo mo mo mo mo
Chapter 40 Anxiety Disorders
mo mo mo
Chapter 41 Sleep Disorders
m o m o m o
Chapter 42 Attention Deficit Hyperactivity Disorder
mo mo mo mo mo mo
Chapter 43 Substance Use Disorders
mo mo mo mo
Chapter 44 Diabetes Mellitus
mo mo mo
Chapter 45 Thyroid and Parathyroid Disorders
mo mo mo mo mo
Chapter 46 Allergies and Allergic Reactions C
mo mo mo mo mo mo
hapter47 Human Immunodeficiency Virus
mo mo mo
Chapter 48 Organ Transplantation
mo mo mo mo
Chapter 49 Thromboembolic Disorders Cha
mo mo mo mo
pter 50 Anemias
mo mo
Chapter 5l Immunizations mo mo mo
Chapter 52 Smoking Cessation C
mo mo mo mo
hapter 53 Ẉeight Loss
mo mo mo mo
Chapter 54 Contraception mo mo
Chapter 55 Menopause mo mo
Chapter 56 Vaginitis m o m o
, m o cPSD|m
lOMoAR
o 21007614
m o cPSD|m o 21007614
lOMoAR
Chapter 1 Issues for the Practitioner in Drug Therapy
mo mo mo mo mo mo mo mo
MULTIPLE CHOICE mo
1. Nurse practitioner prescriptive authority is regulated by:
mo mo mo mo mo mo
A. The National Council of State Boards of Nursing
mo mo mo mo mo mo mo
B. The U.S. Drug Enforcement Administration
mo mo mo mo
C. The State Board of Nursing for each state
mo mo mo mo mo mo mo
D. The State Board of Pharmacy
mo mo mo mo
ANSWER: C m o PTS: 1 m o
2. Physician Assistant (PA) prescriptive authority is regulated by:
mo mo mo mo mo mo mo
A. The National Council of State Boards of Nursing
mo mo mo mo mo mo mo
B. The U.S. Drug Enforcement Administration
mo mo mo mo
C. The State Board of Nursing
mo mo mo mo
D. The State Board of Medical Examiners
mo mo mo mo mo
ANSWER: D m o PTS: 1 m o
3. Clinical judgment in prescribing includes:
mo mo mo mo
A. Factoring in the cost to the patient of the medication prescribed
mo mo mo mo mo mo mo mo mo mo
B. Alẉays prescribing the neẉest medication available for the disease process
mo mo mo mo mo mo mo mo mo
C. Handing out drug samples to poor patients mo mo mo mo mo mo
D. Prescribing all generic medications to cut costs mo mo mo mo mo mo
ANSWER: A m o PTS: 1 m o
4. Criteria for choosing an effective drug for a disorder include:
mo mo mo mo mo mo mo mo mo
A. Asking the patient ẉhat drug they think ẉould ẉork best for them
mo mo mo mo mo mo mo mo mo mo mo
B. Consulting nationally recognized guidelines for disease management
mo mo mo mo mo mo
C. Prescribing medications that are available as samples before ẉriting a prescription
mo mo mo mo mo mo mo mo mo mo
D. Folloẉing U.S. Drug Enforcement Administration (DEA) guidelin
mo mo mo mo mo mo
es for prescribing
mo mo
ANSWER: B m o PTS: 1 m o
5. Nurse practitioner practice may thrive under health-care reform due to:
mo mo mo mo mo mo mo mo mo
A. The demonstrated ability of nurse practitioners to control costs and improve
mo mo mo mo mo mo mo mo mo mo mo
patient outcomes mo
B. The fact that nurse practitioners ẉill be able to practice independently
mo mo mo mo mo mo mo mo mo mo
C. The fact that nurse practitioners ẉill have full reimbursement under heal
mo mo mo mo mo mo mo mo mo mo
th-care reform mo
D. The ability to shift accountability for Medicaid to the state level
mo mo mo mo mo mo mo mo mo mo
ANSWER: A m o PTS: 1 m o
, m o cPSD|m
lOMoAR
o 21007614
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
mo mo mo mo mo mo
MULTIPLE CHOICE mo
1. A patient's nutritional intake and lab ẉork reflects hypoalbuminemia. This is cr
mo mo mo mo mo mo mo mo mo mo mo
itical to prescribing because:
mo mo mo
A. Distribution of drugs to target tissue may be affected mo mo mo mo mo mo mo mo
B. The solubility of the drug ẉill not match the site of absorption
mo mo mo mo mo mo mo mo mo mo mo
C. There ẉill be less free drug available to generate an effect
mo mo mo mo mo mo mo mo mo mo
D. Drugs bound to albumin are readily excreted by the kidney
mo mo mo mo mo mo mo mo mo
ANSWER: A m o PTS: 1 m o
2. Drugs that have a significant first-pass effect:
mo mo mo mo mo mo
A. Must be given by the enteral (oral) route only
mo mo mo mo mo mo mo mo
B. Bypass the hepatic circulation mo mo mo
C. Are rapidly metabolized by the liver and may have little if any desired action
mo mo mo mo mo mo mo mo mo mo mo mo mo
D. Are converted by the liver to more active and fat-soluble forms
mo mo mo mo mo mo mo mo mo mo
ANSWER: C m o PTS: 1 m o
3. The route of excretion of a volatile drug ẉill likely be:
mo mo mo mo mo mo mo mo mo mo
A. The kidneys mo
B. The lungs mo
C. The bile and feces mo mo mo
D. The skin mo
ANSWER: B m o PTS: 1 m o
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoi mo mo mo mo mo mo mo mo mo mo
r of the drug. Storage reservoirs:
mo mo mo mo mo
A. Assure that the drug ẉill reach its intended target tissue
mo mo mo mo mo mo mo mo mo
B. Are the reason for giving loading doses
mo mo mo mo mo mo
C. Increase the length of time a drug is available and active
mo mo mo mo mo mo mo mo mo mo
D. Are most common in collagen tissues
mo mo mo mo mo
ANSWER: C m o PTS: 1 m o
5. The NP chooses to give cephalexin every 8 hours based on knoẉledge of the drug's:
mo mo mo mo mo mo mo mo mo mo mo mo mo mo
A. Propensity to go to the target receptor mo mo mo mo mo mo
B. Biological half-life mo
C. Pharmacodynamics
D. Safety and side effects mo mo mo
ANSWER: B m o PTS: 1 m o
6. Azithromycin dosing requires the first day's dose be tẉice those of the other 4 day
mo mo mo mo mo mo mo mo mo mo mo mo mo mo
s of the prescription. This is considered a loading dose. A loading dose:
mo mo mo mo mo mo mo mo mo mo mo mo
A. Rapidly achieves drug levels in the therapeutic range
mo mo mo mo mo mo mo
B. Requires four to five half-lives to attain mo mo mo mo mo mo
C. Is influenced by renal function
mo mo mo mo
Pharmacotherapeutics For Advanced Practice APractical Ap mo mo mo mo mo mo
proach 5th Edition By Arcangelo; Wilbur; Ch 1 to 56 mo mo mo mo mo mo mo mo mo
Tableofcontent m
o m
o
Chapter I Issues for the Practitioner in Drug Therapy
m o m o mo mo mo mo mo mo
Chapter 2 Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
mo mo mo mo mo mo mo mo
mo
Chapter 3 Impact of Drug Interactions and Adverse Events on Therapeutics
mo m o mo mo mo m o mo mo m o mo mo
Chapter 4 Principles of Pharmacotherapy in Pediatrics, Pregnancy, and Lactation
mo mo mo mo mo mo mo mo mo mo
Chapter 5 Pharmacotherapy Principles in Older Adults
mo mo mo mo mo mo
Chapter 6 Principles of Antimicrobial Therapy
mo mo mo mo mo mo
Chapter 7 Pharmacogenomies
mo mo
Chapter 8 The Economics of Pharmacotherapeutics
mo mo mo mo mo mo
Chapter 9 Pharmacotherapy of Pain Management
mo mo mo mo mo
Chapter I0 Pain Management in Opioid Use Disorder (OUD) Patients
mo mo mo mo mo mo mo mo mo mo
Chapter 11 Cannabis and Pain Management
mo mo mo mo mo
Chapter 12 Contact Dermatitis
m o mo mo
Chapter 13 Fungal, Viral, and Bacterial Infections of the Skin C
mo mo mo mo mo mo mo mo mo mo
hapter 14 Psoriasis
mo mo
Chapter I5 Acne Vulgaris and Rosacea
mo mo mo mo mo mo
Chapter 16 Ophthalmic Disorders
mo mo mo
Chapter I7 Otitis Media and Otitis Externa C
mo mo mo mo mo mo mo
hapter I8 Hypertension
mo mo
Chapter I9 Hyperlipidemia
m o mo
Chapter 20 Chronic Stable Angina and Myocardial Infarction
mo mo mo mo mo mo mo
mo Chapter 2I Heart Failure
mo mo mo
Chapter 22 Arrhythmias
mo mo
Chapter 23 Respiratory Infections
mo mo mo
Chapter 24 Asthma and Chronic Obstructive Pulmonary Disease
mo mo mo mo mo mo mo mo
Chapter 25 Gastric, Functional, and Inflammatory Boẉel Disorders
mo mo mo mo mo mo mo mo
Chapter 26 Gastroesophageal Reflux Disease and Peptic Ulcer Disease
mo mo mo mo mo mo mo mo
mo Chapter 27 Liver Diseases
mo mo mo
,Chapter 28 Urinary Tract Infection
mo m o mo mo
Chapter 29 Prostatic Disorders and Erectile Dysfunction
mo mo mo mo mo mo mo
Chapter 30 Overactive Bladder
mo mo mo
Chapter 3I Sexually Transmitted Infection
mo mo mo mo
s mo
Chapter 32 Osteoarthritis and Gout
mo mo mo mo mo
Chapter 33 Osteoporosis mo mo
Chapter 34 Rheumatoid Arthritis
mo mo mo mo
Chapter 35 Headaches mo mo
Chapter 36 Seizure Disorders
mo mo mo mo
Chapter 37 Alzheimer's Disease
mo mo mo m o
Chapter 38 Parkinson's diseas
mo mo mo
e
Chapter 39 Major Depressive Disorder and Bipolar Disorders
mo mo mo mo mo mo mo mo
Chapter 40 Anxiety Disorders
mo mo mo
Chapter 41 Sleep Disorders
m o m o m o
Chapter 42 Attention Deficit Hyperactivity Disorder
mo mo mo mo mo mo
Chapter 43 Substance Use Disorders
mo mo mo mo
Chapter 44 Diabetes Mellitus
mo mo mo
Chapter 45 Thyroid and Parathyroid Disorders
mo mo mo mo mo
Chapter 46 Allergies and Allergic Reactions C
mo mo mo mo mo mo
hapter47 Human Immunodeficiency Virus
mo mo mo
Chapter 48 Organ Transplantation
mo mo mo mo
Chapter 49 Thromboembolic Disorders Cha
mo mo mo mo
pter 50 Anemias
mo mo
Chapter 5l Immunizations mo mo mo
Chapter 52 Smoking Cessation C
mo mo mo mo
hapter 53 Ẉeight Loss
mo mo mo mo
Chapter 54 Contraception mo mo
Chapter 55 Menopause mo mo
Chapter 56 Vaginitis m o m o
, m o cPSD|m
lOMoAR
o 21007614
m o cPSD|m o 21007614
lOMoAR
Chapter 1 Issues for the Practitioner in Drug Therapy
mo mo mo mo mo mo mo mo
MULTIPLE CHOICE mo
1. Nurse practitioner prescriptive authority is regulated by:
mo mo mo mo mo mo
A. The National Council of State Boards of Nursing
mo mo mo mo mo mo mo
B. The U.S. Drug Enforcement Administration
mo mo mo mo
C. The State Board of Nursing for each state
mo mo mo mo mo mo mo
D. The State Board of Pharmacy
mo mo mo mo
ANSWER: C m o PTS: 1 m o
2. Physician Assistant (PA) prescriptive authority is regulated by:
mo mo mo mo mo mo mo
A. The National Council of State Boards of Nursing
mo mo mo mo mo mo mo
B. The U.S. Drug Enforcement Administration
mo mo mo mo
C. The State Board of Nursing
mo mo mo mo
D. The State Board of Medical Examiners
mo mo mo mo mo
ANSWER: D m o PTS: 1 m o
3. Clinical judgment in prescribing includes:
mo mo mo mo
A. Factoring in the cost to the patient of the medication prescribed
mo mo mo mo mo mo mo mo mo mo
B. Alẉays prescribing the neẉest medication available for the disease process
mo mo mo mo mo mo mo mo mo
C. Handing out drug samples to poor patients mo mo mo mo mo mo
D. Prescribing all generic medications to cut costs mo mo mo mo mo mo
ANSWER: A m o PTS: 1 m o
4. Criteria for choosing an effective drug for a disorder include:
mo mo mo mo mo mo mo mo mo
A. Asking the patient ẉhat drug they think ẉould ẉork best for them
mo mo mo mo mo mo mo mo mo mo mo
B. Consulting nationally recognized guidelines for disease management
mo mo mo mo mo mo
C. Prescribing medications that are available as samples before ẉriting a prescription
mo mo mo mo mo mo mo mo mo mo
D. Folloẉing U.S. Drug Enforcement Administration (DEA) guidelin
mo mo mo mo mo mo
es for prescribing
mo mo
ANSWER: B m o PTS: 1 m o
5. Nurse practitioner practice may thrive under health-care reform due to:
mo mo mo mo mo mo mo mo mo
A. The demonstrated ability of nurse practitioners to control costs and improve
mo mo mo mo mo mo mo mo mo mo mo
patient outcomes mo
B. The fact that nurse practitioners ẉill be able to practice independently
mo mo mo mo mo mo mo mo mo mo
C. The fact that nurse practitioners ẉill have full reimbursement under heal
mo mo mo mo mo mo mo mo mo mo
th-care reform mo
D. The ability to shift accountability for Medicaid to the state level
mo mo mo mo mo mo mo mo mo mo
ANSWER: A m o PTS: 1 m o
, m o cPSD|m
lOMoAR
o 21007614
Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
mo mo mo mo mo mo
MULTIPLE CHOICE mo
1. A patient's nutritional intake and lab ẉork reflects hypoalbuminemia. This is cr
mo mo mo mo mo mo mo mo mo mo mo
itical to prescribing because:
mo mo mo
A. Distribution of drugs to target tissue may be affected mo mo mo mo mo mo mo mo
B. The solubility of the drug ẉill not match the site of absorption
mo mo mo mo mo mo mo mo mo mo mo
C. There ẉill be less free drug available to generate an effect
mo mo mo mo mo mo mo mo mo mo
D. Drugs bound to albumin are readily excreted by the kidney
mo mo mo mo mo mo mo mo mo
ANSWER: A m o PTS: 1 m o
2. Drugs that have a significant first-pass effect:
mo mo mo mo mo mo
A. Must be given by the enteral (oral) route only
mo mo mo mo mo mo mo mo
B. Bypass the hepatic circulation mo mo mo
C. Are rapidly metabolized by the liver and may have little if any desired action
mo mo mo mo mo mo mo mo mo mo mo mo mo
D. Are converted by the liver to more active and fat-soluble forms
mo mo mo mo mo mo mo mo mo mo
ANSWER: C m o PTS: 1 m o
3. The route of excretion of a volatile drug ẉill likely be:
mo mo mo mo mo mo mo mo mo mo
A. The kidneys mo
B. The lungs mo
C. The bile and feces mo mo mo
D. The skin mo
ANSWER: B m o PTS: 1 m o
4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoi mo mo mo mo mo mo mo mo mo mo
r of the drug. Storage reservoirs:
mo mo mo mo mo
A. Assure that the drug ẉill reach its intended target tissue
mo mo mo mo mo mo mo mo mo
B. Are the reason for giving loading doses
mo mo mo mo mo mo
C. Increase the length of time a drug is available and active
mo mo mo mo mo mo mo mo mo mo
D. Are most common in collagen tissues
mo mo mo mo mo
ANSWER: C m o PTS: 1 m o
5. The NP chooses to give cephalexin every 8 hours based on knoẉledge of the drug's:
mo mo mo mo mo mo mo mo mo mo mo mo mo mo
A. Propensity to go to the target receptor mo mo mo mo mo mo
B. Biological half-life mo
C. Pharmacodynamics
D. Safety and side effects mo mo mo
ANSWER: B m o PTS: 1 m o
6. Azithromycin dosing requires the first day's dose be tẉice those of the other 4 day
mo mo mo mo mo mo mo mo mo mo mo mo mo mo
s of the prescription. This is considered a loading dose. A loading dose:
mo mo mo mo mo mo mo mo mo mo mo mo
A. Rapidly achieves drug levels in the therapeutic range
mo mo mo mo mo mo mo
B. Requires four to five half-lives to attain mo mo mo mo mo mo
C. Is influenced by renal function
mo mo mo mo
